Valetudo Therapeutics LLC bought LIMN

Footnotes

Consists of 5,244,351 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On July 2, 2026, Valetudo received 3,448,926 shares of common stock and 48,975.10742 shares of the registrant's newly designated Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") as consideration paid to former members of InnocsAI LLC ("InnocsAI") in connection with the registrant's acquisition of InnocsAI. Each share of Series A Preferred Stock will be convertible into 10,000 shares of common stock at an issue price of $0.20 per share, which conversion is contingent upon prior stockholder approval of the issuance of the underlying common shares to the extent required under applicable Nasdaq Stock Market LLC listing rules.; The Series A Preferred Stock has no expiration date. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.